Randomized Trialhigh evidence
4% Tetrasodium EDTA to Prevent Central Venous Access Device-Associated Complications: A Randomized Clinical Trial.
JAMA·June 23, 2026·PMID 42150112
Why it mattersCentral venous access device complications are common in the ICU, leading to morbidity, delays, and costs. A locking solution that reduces occlusions and potentially infections offers a practical, low-risk intervention to improve catheter function and patient safety.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled